Lupin Ltd is the pharmaceutical company that has to foray into diagnostics to leverage its ‘doctor connect to tap a sector that has low entry barriers, gives high returns on capital employed, and is witnessing double-digit growth. A formal launch is expected next month, media reported.
- Alteria Capital Successfully Closes the Fund III Venture Debt Scheme at Rs 19.5 Crore
- Finance Ministry to Borrow Rs 7.5 lakh Crore in H1FY25, Plans to Raise Sovereign Green Bonds
- Reliance Power to Settle Debt Worth Rs 1,023 Crore With Authum Investment’s Arm
- BHEL Shares Rally 4% on Bagging Rs 4,000 Crore Order
- Gartner Survey Shows AI-Related Risks see Greatest Audit Coverage Increases in 2024
Lupin Diagnostics will be a part of Lupin Healthcare, a 100 per cent subsidiary of Lupin. It is in the process of recruiting the team, finalising franchise partners, and setting up a 45,000 square feet laboratory in Navi Mumbai.
Stock Covered in the news